Plain-English translation of NCT06551519 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Sclerosis research guide →This study is observing how a specific blood marker called serum neurofilament (sNfL) can help doctors better manage relapsing multiple sclerosis. Researchers will collect this blood marker information along with routine medical care to understand whether measuring this marker helps predict how active your MS is and improves treatment decisions — either staying on your current MS medication or switching to ofatumumab.
Doctors need better tools to predict which patients' MS will worsen and when treatment changes are necessary. This study explores whether tracking this blood marker in routine care can help doctors catch disease activity earlier and make smarter decisions about whether to continue current treatment or switch to a different medication.
You will continue your normal medical care with your MS doctor over up to 24 months, with visits scheduled as your doctor usually does. During these routine visits, your doctor will collect the blood marker information and other standard data about your MS disease activity. You are not required to do anything extra — the study simply observes and records information that is already part of your normal care as you either stay on your current medication or switch to ofatumumab.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
Germany